Bimagrumab
CAS No. 1356922-05-8
Bimagrumab ( —— )
产品货号. M36745 CAS No. 1356922-05-8
Bimagrumab (Anti-ACVR2B Reference Antibody) 是一种人单克隆抗体,可阻断激活素 II 型受体 (ActRII),对 ActRIIB 和 ActRIIA 的 KD 值分别为 1.7 pM 和 434 pM。Bimagrumab 可用于病理性肌肉损失和无力的研究。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥5216 | 有现货 |
|
| 10MG | ¥7106 | 有现货 |
|
| 25MG | ¥10137 | 有现货 |
|
| 50MG | ¥13764 | 有现货 |
|
| 100MG | ¥17820 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Bimagrumab
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Bimagrumab (Anti-ACVR2B Reference Antibody) 是一种人单克隆抗体,可阻断激活素 II 型受体 (ActRII),对 ActRIIB 和 ActRIIA 的 KD 值分别为 1.7 pM 和 434 pM。Bimagrumab 可用于病理性肌肉损失和无力的研究。
-
产品描述Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness.
-
体外实验——
-
体内实验——
-
同义词——
-
通路Others
-
靶点Other Targets
-
受体Others
-
研究领域——
-
适应症——
化学信息
-
CAS Number1356922-05-8
-
分子量Approximately 142.78 kDa.
-
分子式——
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Heymsfield SB, et, al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021 Jan 4;4(1):e2033457. ?
产品手册
关联产品
-
cis-Mulberroside A
cis-Mulberroside A shows high analgesic and anti-inflammatory activities, it can protect mice against ethanol-induced hepatic damage.
-
Dehydrojuncusol
Dehydrojuncusol, a new inhibitor of hepatitis C virus RNA replication, it inhibits infection of different HCV genotypes by targeting the NS5A protein and is active against resistant HCV variants frequently found in patients with treatment failure.
-
Volagidemab
Volagidemab 是一种拮抗性 胰高血糖素受体 (GCGR) 单克隆抗体 (mAb)。Volagidemab 可用于1型糖尿病 (T1D) 的研究。
021-51111890
购物车()
sales@molnova.cn

